Article and Video CATEGORIES

Cancer Journey

Search By

Assistant Professor of Medicine, Hospital of the University of Pennsylvania, and the Veteran’s Administration Medical Center

ASCO/ESMO 2020 - KEYNOTE 048 Study Update, What Have We Learned?
ASCO/ESMO 2020 - KEYNOTE 048 Study Update, What Have We Learned?
First Line Regiments of Pembrolizumab Monotherapy vs. Pembrolizumab and Chemo for Patients with Recurrent or Metastatic HNSCC
Author
Joshua Bauml, MD, Advisory Board Member, GRACE Faculty
Image
We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials.

Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program.

Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University of Maryland, on the newest updates to 2020 trials and studies presented at ASCO and ESMO this year.

 

For this discussion, Drs. Bauml, Weiss, Gold and Mehra discuss what we have learned from Keynote 048: First Line Regiments of Pembrolizumab Monotherapy vs. Pembrolizumab and Chemo for Patients with Recurrent or Metastatic HNSCC

We thank Varian for their support of this program!

 

To join the conversation, visit https://cancergrace.org/forum.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Hi Hopish hope,  Welcome to…
By JanineT GRACE … on
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on